XTSXVXL
Market cap953kUSD
May 22, Last price
0.01CAD
Name
Vaxil Bio Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.98%
Rev. gr., 5y
%
Revenues
0k
Net income
0k
L-99.96%
CFO
-561k
L-23.57%
Profile
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2015‑05 | 2014‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | 254 | 584 | 992 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (254) | (584) | (992) | ||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | (254) | (584) | (992) | ||||||||
Net income | (254) -99.96% | (584) -40.77% | (986) -27.98% | ||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | 1,817 | ||||||||||
BB yield | -17.80% | ||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | (938) | (1,510) | (2,241) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (561) | (734) | (1,084) | ||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | 1,808 | ||||||||||
FCF | (254) | (582) | (967) | ||||||||
| Balance | |||||||||||
Cash | 938 | 1,510 | 2,241 | ||||||||
Long term investments | |||||||||||
Excess cash | 938 | 1,510 | 2,241 | ||||||||
Stockholders' equity | 891 | 812 | 1,342 | ||||||||
Invested Capital | 324 | 358 | |||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | 136,978 | 136,979 | 136,102 | ||||||||
Price | 0.03 25.00% | 0.02 -73.33% | 0.08 -75.00% | ||||||||
Market cap | 3,424 25.00% | 2,740 -73.16% | 10,208 -66.56% | ||||||||
EV | 2,486 | 1,230 | 7,967 | ||||||||
EBITDA | (254) | (582) | (967) | ||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||